HomeNuminus Wellness Inc.

Numinus Wellness Inc.

Numinus Grows Rapidly With New Clinical and Facility Expansions

Numinus Grows Rapidly With New Clinical and Facility Expansions

November 11, 2021

Numinus to Host Extension of MAPS-Sponsored MDMA-Assisted Therapy for PTSD Trials

November 10, 2021

Numinus to Participate in Microdose Hosted Events: Psychedelic Capital and Wonderland: Miami

October 27, 2021

Numinus Advances Phase 1 Trial on Proprietary Psilocybin Product

October 20, 2021

Numinus to Present at the KCSA Psychedelics Virtual Investor Conference on October 14th

October 6, 2021

Numinus Completes Acquisition of Neurology Centre of Toronto

Numinus Completes Acquisition of Neurology Centre of Toronto

September 24, 2021

Numinus to Participate in Upcoming Investor Conferences in September 2021

Numinus to Participate in Upcoming Investor Conferences in September 2021

September 3, 2021

Numinus Wellness Closes Q3 2021 With $63.2 Million Cash Position, Lab and Trial Advances, and Strategic Expansion into Psychedelic Neurology

Numinus Wellness Closes Q3 2021 With $63.2 Million Cash Position, Lab and Trial Advances, and Strategic Expansion into Psychedelic Neurology

July 30, 2021

Numinus Announces Health Canada Approval of MAPS-Sponsored Open Label Study for MDMA-Assisted Therapy for PTSD

Numinus Announces Health Canada Approval of MAPS-Sponsored Open Label Study for MDMA-Assisted Therapy for PTSD

July 12, 2021

Numinus Wellness To Acquire Neurology Centre of Toronto, Plans to Create Centre for Psychedelic Neurology

Numinus Wellness To Acquire Neurology Centre of Toronto, Plans to Create Centre for Psychedelic Neurology

July 6, 2021

« 1 2 3 4 5 »